A Phase 2 interventional study of Naltrexone SR 32 mg/bupropion SR 360 mg/day and Placebo in Obesity, sponsored by Orexigen Therapeutics, Inc. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2015-01-06.
Sponsored by Orexigen Therapeutics, Inc · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing naltrexone in Obesity — 4 open to participants now, 4 under way, none of them phase 3. Naltrexone · Obesity.
Among the 23 studies testing naltrexone in Obesity, this one is the 14th largest by enrollment, is one of 3 that started in 2008, is one of 5 in phase 2, and was the 8th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →4 of the 23 studies testing naltrexone in Obesity are open now, in 2 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–65
Laval University · Sites in Canada
Ages 18–65
Medical University of South Carolina · Sites in United States
Ages 18–65
Medical University of South Carolina · Sites in United States
Ages 18–65
By country, each count listing its studies:
Naltrexone: first FDA approval 1984 (REVIA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 7 · Phase 4 6
First in 2005; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 67 across the 23 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 23 have an industry lead sponsor. The 10 most frequent:
Orexigen Therapeutics, Inc is the lead sponsor of 18 studies on the registry; none are open to participants now.
14 studies in Obesity by Orexigen Therapeutics, Inc: none open now, none under way, none of them phase 3. Of 14 finished, 8 (57%) have results posted.
Among the 14 studies in Obesity by Orexigen Therapeutics, Inc, this one is the 12th largest by enrollment, is one of 3 that started in 2008, is one of 6 in phase 2, and was the 10th registered.
Orexigen Therapeutics, Inc’s Obesity studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing naltrexone in Obesity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Orexigen Therapeutics, Inc’s 14 in Obesity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess the effect of naltrexone SR/bupropion SR (NB) on brain function in response to food cues using functional magnetic resonance imaging in overweight or obese subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Naltrexone SR 32 mg/bupropion SR 360 mg/day
Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/day · Other: fMRI scan
Placebo tablets
Drug: Placebo · Other: fMRI scan
Drug page: Naltrexone
fMRI to assess the effects of the drug/placebo on areas of the brain
Also known as: functional magnetic resonance imaging to assess the effects of the drug/placebo on areas of the brain
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Superior Frontal
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.
Time frame: Baseline, 4 weeks
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Anterior Cingulate
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.
Time frame: Baseline, 4 weeks
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Hippocampal Region 1
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.
Time frame: Baseline, 4 weeks
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Hippocampal Region 2
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.
Time frame: Baseline, 4 weeks
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Superior Parietal
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.
Time frame: Baseline, 4 weeks
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Posterior Insula
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.
Time frame: Baseline, 4 weeks
Percent Change in Body Weight
Time frame: Baseline, 4 weeks
Dutch Eating Behavior Questionnaire - Change in Restrained Eating Subscale Score
The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Restrained Eating subscale consisted of 10 items and the scores ranged from 10 (worse outcome) to 50 (better outcome).
Time frame: Baseline, 4 weeks
Dutch Eating Behavior Questionnaire - Change in Emotional Eating A Subscale Score
The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Emotional Eating A subscale (clearly labeled emotions) consisted of 9 items and the scores ranged from 9 (better outcome) to 45 (worse outcome).
Time frame: Baseline, 4 weeks
Dutch Eating Behavior Questionnaire - Change in Emotional Eating B Subscale Score
The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Emotional Eating B subscale (diffuse emotions) consisted of 4 items and the scores ranged from 4 (better outcome) to 20 (worse outcome).
Time frame: Baseline, 4 weeks
Dutch Eating Behavior Questionnaire - Change in External Eating Subscale Score
The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The External Eating subscale consisted of 10 items and the scores ranged from 10 (better outcome) to 50 (worse outcome).
Time frame: Baseline, 4 weeks
Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult
Time frame: Baseline, 4 weeks
| Milestone | NB32 | Placebo |
|---|---|---|
| Started | 23 | 23 |
| Completed | 20 | 20 |
| Not completed | 3 | 3 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Noncompliance | 0 | 1 |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.
| percent activation | Placebo | NB32 |
|---|---|---|
| Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Superior Frontal | -0.35 (-0.48 to -0.22) | 0.34 (0.21 to 0.47) |
| percentage of body weight | NB32 | Placebo |
|---|---|---|
| Percent Change in Body Weight | -0.99 ± 0.44 | -0.43 ± 0.44 |
The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Restrained Eating subscale consisted of 10 items and the scores ranged from 10 (worse outcome) to 50 (better outcome).
| units on a scale | NB32 | Placebo |
|---|---|---|
| Dutch Eating Behavior Questionnaire - Change in Restrained Eating Subscale Score | 1.47 ± 0.86 | 1.87 ± 0.86 |
The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Emotional Eating A subscale (clearly labeled emotions) consisted of 9 items and the scores ranged from 9 (better outcome) to 45 (worse outcome).
| units on a scale | NB32 | Placebo |
|---|---|---|
| Dutch Eating Behavior Questionnaire - Change in Emotional Eating A Subscale Score | -1.16 ± 0.77 | 0.48 ± 0.77 |
The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Emotional Eating B subscale (diffuse emotions) consisted of 4 items and the scores ranged from 4 (better outcome) to 20 (worse outcome).
| units on a scale | NB32 | Placebo |
|---|---|---|
| Dutch Eating Behavior Questionnaire - Change in Emotional Eating B Subscale Score | -0.90 ± 0.55 | 0.45 ± 0.55 |
The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The External Eating subscale consisted of 10 items and the scores ranged from 10 (better outcome) to 50 (worse outcome).
| units on a scale | NB32 | Placebo |
|---|---|---|
| Dutch Eating Behavior Questionnaire - Change in External Eating Subscale Score | -2.64 ± 1.03 | -0.16 ± 1.03 |
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult
| units on a scale | NB32 | Placebo |
|---|---|---|
| Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire | -13.55 ± 4.67 | -4.14 ± 4.41 |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.
| percent activation | Placebo | NB32 |
|---|---|---|
| Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Anterior Cingulate | -0.42 (-0.52 to -0.32) | 0.16 (0.04 to 0.28) |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.
| percent activation | Placebo | NB32 |
|---|---|---|
| Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Hippocampal Region 1 | -0.16 (-0.32 to 0.00) | 0.60 (0.40 to 0.80) |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.
| percent activation | Placebo | NB32 |
|---|---|---|
| Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Hippocampal Region 2 | -0.79 (-0.99 to -0.59) | 0.21 (0.01 to 0.41) |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.
| percent activation | Placebo | NB32 |
|---|---|---|
| Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Superior Parietal | -0.56 (-0.87 to -0.25) | 0.74 (0.34 to 1.04) |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.
| percent activation | Placebo | NB32 |
|---|---|---|
| Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Posterior Insula | -0.16 (-0.25 to -0.07) | 0.30 (0.20 to 0.40) |
Collected over baseline to week 4. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NB32 | — | 0/23 (0%) | 10/23 (43.5%) |
| Placebo | — | 0/22 (0%) | 2/22 (9.1%) |
| Event | NB32 | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 5/23 | 0/22 |
| VomitingGastrointestinal disorders | 5/23 | 0/22 |
| HeadacheNervous system disorders | 3/23 | 1/22 |
| AnxietyPsychiatric disorders | 2/23 | 0/22 |
| MigraineNervous system disorders | 0/23 | 1/22 |
| ConstipationGastrointestinal disorders | 1/23 | 0/22 |
| DizzinessNervous system disorders | 1/23 | 0/22 |
| DepressionPsychiatric disorders | 1/23 | 0/22 |
| PalpitationsCardiac disorders | 1/23 | 0/22 |
| Feeling abnormalGeneral disorders | 1/23 | 0/22 |
Randomized subjects
| Age, Continuous(years) | NB32 | Placebo | Total |
|---|---|---|---|
| Mean | 30.96 ± 7.68 | 30.39 ± 8.46 | 30.67 ± 7.99 |
| Sex: Female, Male(Participants) | NB32 | Placebo | Total |
|---|---|---|---|
| Female | 23 | 23 | 46 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | NB32 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 12 | 8 | 20 |
| White | 3 | 8 | 11 |
| Other | 7 | 5 | 12 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Weight(kg) | NB32 | Placebo | Total |
|---|---|---|---|
| Mean | 87.70 ± 15.83 | 89.59 ± 13.34 | 88.64 ± 14.50 |
| BMI(kg/m^2) | NB32 | Placebo | Total |
|---|---|---|---|
| Mean | 32.96 ± 4.30 | 31.80 ± 3.10 | 32.38 ± 3.75 |
The record gives a start of Sep 2008, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 4 years 7 months after primary completion. A results delay was requested in Oct 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naltrexone
Orexigen Therapeutics, Inc